10-K: Neumora Therapeutics Reports 2024 Financial Results, Provides Clinical Pipeline Update

Neumora Therapeutics' 10-K filing summarizes the company's financial performance for 2024 and provides updates on its clinical-stage neuroscience programs.

Summary

• Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases.
• The company's pipeline includes seven neuroscience programs, with two in clinical development.
• Navacaprant (NMRA-140) is in Phase 3 development for major depressive disorder (MDD), with topline data expected in the first and second quarters of 2026.
• NMRA-511 is in a Phase 1b study for agitation associated with dementia due to Alzheimer's disease (AD), with data expected by the end of 2025.
• The company expects to progress its next M4 PAM into the clinic by mid-2025.
• KOASTAL-1 study did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-sberg Depression Rating Scale (MADRS) total score at Week 6 or the key secondary endpoint of a change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) scale.
• In January 2025, Neumora announced results from the first study in the KOASTAL program, KOASTAL-1.
• Neumora plans to make adjustments to the site selection, medical monitoring and screening tools included in KOASTAL-2 and KOASTAL-3.
• The company had $307.6 million in cash, cash equivalents, and marketable securities as of December 31, 2024.
• Neumora believes its existing resources will fund operations through at least the next 12 months.
• The company reported net losses of $243.8 million, $235.9 million, and $130.9 million for the years ended December 31, 2024, 2023, and 2022, respectively.
• The company expects expenses to increase as it continues clinical development and operates as a public company.
• In October 2024, Neumora entered into a sales agreement with Leerink Partners LLC to sell shares of its common stock, from time to time, with aggregate gross sales proceeds of up to $300.0 million, through an at-the-market equity offering program.
• During the year ended December 31, 2024, Neumora received aggregate net proceeds of $13.7 million through sales of shares of its common stock under the ATM after deducting commissions and offering expenses of $0.8 million.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has a solid cash position and is advancing its pipeline, it is also operating at a loss and has experienced a setback in one of its clinical trials. The sentiment is neutral, reflecting both positive and negative aspects.

Positives

• The company has a diversified pipeline with multiple programs in development.
• Neumora has a strong cash position to fund ongoing operations.
• The company is actively working to advance its clinical programs and progress new candidates into the clinic.

Negatives

• The company is currently operating at a loss and expects to continue to do so for the foreseeable future.
• The KOASTAL-1 study did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-sberg Depression Rating Scale (MADRS) total score at Week 6 or the key secondary endpoint of a change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) scale.

Risks

• Clinical trial results may not be predictive of future outcomes.
• Regulatory approvals are lengthy, time-consuming, and unpredictable.
• The company relies on third parties for manufacturing and clinical trials.
• The company operates in a highly competitive industry.
• The company may require additional funding in the future.
• The company is subject to various healthcare laws and regulations.
• The company is exposed to potential product liability claims.
• The company is subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anticorruption laws, and antimoney laundering laws and regulations.
• The company is subject to potential liability related to the privacy of health information it utilizes in the development of product candidates, as well as information it obtains from clinical trials sponsored by it from research institutions and directly from individuals.

Future Outlook

The company expects to continue to incur significant losses for the foreseeable future as it continues to advance the development of its product candidates and approach, and incur additional costs associated with being a public company. The company believes that its existing cash, cash equivalents and marketable securities will enable it to fund its operating expenses and capital expenditure requirements through at least the next 12 months following the issuance of the consolidated financial statements.

Management Comments

• Neumora expects to report topline data from KOASTAL-3 in the first quarter of 2026 and KOASTAL-2 in the second quarter of 2026.
• Neumora expects to report topline data from this Phase 1b study by the end of 2025.

Industry Context

Neumora competes with multiple biopharmaceutical and biotechnology companies that are similarly working to develop therapeutics targeting neuropsychiatric disorders and neurodegenerative diseases. Notable competitors include traditional biopharmaceutical and biotechnology companies targeting brain diseases such as Axsome Therapeutics; Denali Therapeutics; Neurocrine Biosciences; Prothena Corporation; and Xenon Pharmaceuticals.

Comparison to Industry Standards

• The document mentions that over $110 billion has been spent on neuroscience research and development since 2019 in the United States alone, representing approximately 33% of all disease-specific spending.
• The document mentions that from 2011 to 2020, clinical development success rates for new drug candidates that employed patient selection biomarkers were approximately 16% compared to approximately 8% for patients without patient selection biomarkers according to the BIO.

Management Changes

Legal Proceedings

• On February 6, 2025, a purported stockholder of the Company filed a lawsuit against us, certain of our executive officers, and certain underwriters in the United States District Court for the Southern District of New York alleging violations of the Securities Act related to our initial public offering on September 15, 2023.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical trial results will impact shareholder value.
• Employees: The company's ability to attract and retain talent is crucial for its success.
• Patients: The company's success in developing new treatments will impact patients suffering from brain diseases.

Next Steps

• Report topline data from KOASTAL-3 in the first quarter of 2026.
• Report topline data from KOASTAL-2 in the second quarter of 2026.
• Report data from the Phase 1b study of NMRA-511 by the end of 2025.
• Progress the next M4 PAM into the clinic by mid-2025.

Key Dates